|
1
|
Mahdavifar N, Ghoncheh M, Pakzad R,
Momenimovahed Z and Salehiniya H: Epidemiology, incidence and
mortality of bladder cancer and their relationship with the
development index in the world. Asian Pac J Cancer Prev.
17:381–386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ederer IA, Lucca I, Hofbauer SL, Haidinger
M, Haitel A, Susani M, Shariat SF and Klatte T: Histopathology and
prognosis of de novo bladder tumors following solid organ
transplantation. World J Urol. 33:2087–2093. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Leitner CV, Ederer IA, de Martino M,
Hofbauer SL, Lucca I, Mbeutcha A, Mathieu R, Haitel A, Susani M,
Shariat SF and Klatte T: Dynamic prognostication using conditional
recurrence and progression estimates for patients with nonmuscle
invasive bladder cancer. J Urol. 196:46–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Svatek RS, Hollenbeck BK, Holmäng S, Lee
R, Kim SP, Stenzl A and Lotan Y: The economics of bladder cancer:
Costs and considerations of caring for this disease. Eur Urol.
66:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sountoulides P, Mykoniatis I and Metaxa L:
Non-visible asymptomatic haematuria: A review of the guidelines
from the urologist's perspective. Expert Rev Anticancer Ther.
17:203–216. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon
TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R,
Todenhöfer T, Vlahou A, et al: Microhematuria assessment an IBCN
consensus-Based upon a critical review of current guidelines. Urol
Oncol. 34:437–451. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan WS, Sarpong R, Khetrapal P, Rodney S,
Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, et
al: Can renal and bladder ultrasound replace computerized
tomography urogram in patients investigated for microscopic
hematuria? J Urol. 200:973–980. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bensalah K, Montorsi F and Shariat SF:
Challenges of cancer biomarker profiling. Eur Urol. 52:1601–1609.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Martino M, Lucca I, Mbeutcha A, Wiener
HG, Haitel A, Susani M, Shariat SF and Klatte T: Carbonic anhydrase
IX as a diagnostic urinary marker for urothelial bladder cancer.
Eur Urol. 68:552–554. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Martino M, Shariat SF, Hofbauer SL,
Lucca I, Taus C, Wiener HG, Haitel A, Susani M and Klatte T: Aurora
A Kinase as a diagnostic urinary marker for urothelial bladder
cancer. World J Urol. 33:105–110. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hofbauer SL, de Martino M, Lucca I, Haitel
A, Susani M, Shariat SF and Klatte T: A urinary microRNA (miR)
signature for diagnosis of bladder cancer. Urol Oncol.
36:531.e1–531.e8. 2018. View Article : Google Scholar
|
|
12
|
Chang Y, Xu J and Zhang Q: Microplate
magnetic chemiluminescence immunoassay for detecting urinary
survivin in bladder cancer. Oncol Lett. 14:4043–4052. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin T, Liu Z, Liu L, Yang L, Han P, Zhang
P and Wei Q: Prospective evaluation of fluorescence in situ
hybridization for diagnosing urothelial carcinoma. Oncol Lett.
13:3928–3934. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu X, Li P, Fu D, Wei Z, Xu S, Xu F, Tian
F, Ge J, Zhang Z and Cheng W: Combined use of urinary Survivin
detection and liquid-based cytology for the early diagnosis of
bladder urothelial carcinoma. Oncol Lett. 15:7739–7743.
2018.PubMed/NCBI
|
|
15
|
Yang Y, Xu J and Zhang Q: Detection of
urinary survivin using a magnetic particles-based chemiluminescence
immunoassay for the preliminary diagnosis of bladder cancer and
renal cell carcinoma combined with LAPTM4B. Oncol Lett.
15:7923–7933. 2018.PubMed/NCBI
|
|
16
|
Li HT, Duymich CE, Weisenberger DJ and
Liang G: Genetic and epigenetic alterations in bladder cancer. Int
Neurourol J. 20 (Suppl 2):S84–S94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lyko F: The DNA methyltransferase family:
A versatile toolkit for epigenetic regulation. Nat Rev Genet.
19:81–92. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union Against Cancer. TNM Classification of
Malignant Tumours (7th). Wiley-Blackwell. (Chichester). 2009.
|
|
19
|
Miyamoto H, Miller JS, Fajardo DA, Lee TK,
Netto GJ and Epstein JI: Non-invasive papillary urothelial
neoplasms: The 2004 WHO/ISUP classification system. Pathol Int.
60:1–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3:RESEARCH00342002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sapre N, Anderson PD, Costello AJ, Hovens
CM and Corcoran NM: Gene-based urinary biomarkers for bladder
cancer: An unfulfilled promise? Urol Oncol. 32:48.e9–17. 2014.
View Article : Google Scholar
|
|
23
|
Bannister AJ and Kouzarides T: Regulation
of chromatin by histone modifications. Cell Res. 21:381–395. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hull EE, Montgomery MR and Leyva KJ: HDAC
Inhibitors as epigenetic regulators of the immune system: Impacts
on cancer therapy and inflammatory diseases. Biomed Res Int.
2016:87972062016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Poyet C, Jentsch B, Hermanns T,
Schweckendiek D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild
PJ and Kristiansen G: Expression of histone deacetylases 1, 2 and 3
in urothelial bladder cancer. BMC Clin Pathol. 14:102014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Forbes SA, Beare D, Gunasekaran P, Leung
K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et
al: COSMIC: Exploring the world's knowledge of somatic mutations in
human cancer. Nucleic Acids Res. 43:D805–D811. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jeltsch A, Ehrenhofer-Murray A, Jurkowski
TP, Lyko F, Reuter G, Ankri S, Nellen W, Schaefer M and Helm M:
Mechanism and biological role of Dnmt2 in nucleic acid methylation.
RNA Biol. 14:1108–1123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gil VS, Bhagat G, Howell L, Zhang J, Kim
CH, Stengel S, Vega F, Zelent A and Petrie K: Deregulated
expression of HDAC9 in B cells promotes development of
lymphoproliferative disease and lymphoma in mice. Dis Model Mech.
9:1483–1495. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rastogi B, Raut SK, Panda NK, Rattan V,
Radotra BD and Khullar M: Overexpression of HDAC9 promotes oral
squamous cell carcinoma growth, regulates cell cycle progression,
and inhibits apoptosis. Mol Cell Biochem. 415:183–196. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lapierre M, Linares A, Dalvai M,
Duraffourd C, Bonnet S, Boulahtouf A, Rodriguez C, Jalaguier S,
Assou S, Orsetti B, et al: Histone deacetylase 9 regulates breast
cancer cell proliferation and the response to histone deacetylase
inhibitors. Oncotarget. 7:19693–19708. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu CT, Wu CF, Lu CH, Lin CC, Chen WC, Lin
PY and Chen MF: Expression and function role of DNA
methyltransferase 1 in human bladder cancer. Cancer. 117:5221–5233.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang H, Qi D, Li J, Peng T, Yang L, Yuan
J, Zhang Y, Hu Y, Su J, Que B, et al: A novel regulatory circuit of
miR-152 and DNMT1 in human bladder cancer. Oncol Rep. 40:1803–1812.
2018.PubMed/NCBI
|
|
33
|
Pinkerneil M, Hoffmann MJ, Kohlhof H,
Schulz WA and Niegisch G: Evaluation of the therapeutic potential
of the novel isotype specific HDAC inhibitor 4SC-202 in urothelial
carcinoma cell lines. Target Oncol. 11:783–798. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weichert W: HDAC expression and clinical
prognosis in human malignancies. Cancer Lett. 280:168–176. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Junqueira-Neto S, Vieira FQ, Montezuma D,
Costa NR, Antunes L, Baptista T, Oliveira AI, Graça I, Rodrigues Â,
Magalhães JS, et al: Phenotypic impact of deregulated expression of
class I histone deacetylases in urothelial cell carcinoma of the
bladder. Mol Carcinog. 54:523–531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Niegisch G, Knievel J, Koch A, Hader C,
Fischer U, Albers P and Schulz WA: Changes in histone deacetylase
(HDAC) expression patterns and activity of HDAC inhibitors in
urothelial cancers. Urol Oncol. 31:1770–1779. 2013. View Article : Google Scholar : PubMed/NCBI
|
